Metabolic gene expression changes in astrocytes in Multiple Sclerosis cerebral cortex are indicative of immune-mediated signaling  by Zeis, T. et al.
Brain, Behavior, and Immunity 48 (2015) 313–325Contents lists available at ScienceDirect
Brain, Behavior, and Immunity
journal homepage: www.elsevier .com/locate /ybrbiMetabolic gene expression changes in astrocytes in Multiple Sclerosis
cerebral cortex are indicative of immune-mediated signalinghttp://dx.doi.org/10.1016/j.bbi.2015.04.013
0889-1591/ 2015 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations: ANLS, astrocyte–neuron lactate shuttle; GGC, glutamate–glu-
tamine cycle; NAGM, normal appearing cortical gray matter.
⇑ Corresponding author at: Neurobiology, Department of Biomedicine, University
Hospital Basel, University of Basel, Hebelstrasse 20, CH-4031 Basel, Switzerland.
Tel.: +41 61 328 73 94.
E-mail address: Nicole.Schaeren-Wiemers@unibas.ch (N. Schaeren-Wiemers).
1 Deceased March 22, 2011.T. Zeis a, I. Allaman b, M. Gentner a, K. Schroder c,f, J. Tschopp c,1, P.J. Magistretti e,b,d,
N. Schaeren-Wiemers a,⇑
aNeurobiology, Department of Biomedicine, University Hospital Basel, University of Basel, Hebelstrasse 20, CH-4031 Basel, Switzerland
b Laboratory of Neuroenergetics and Cellular Dynamics, Brain Mind Institute, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland
cDepartment of Biochemistry, University of Lausanne, CH-1066 Epalinges, Switzerland
dCentre de Neurosciences Psychiatriques, CHUV, Département de Psychiatrie, Site de Cery, CH-1008 Prilly/Lausanne, Switzerland
eDivision of Biological and Environmental Sciences and Engineering, KAUST, Thuwal, Saudi Arabia
f Institute for Molecular Bioscience, The University of Queensland, St Lucia 4072, Australia
a r t i c l e i n f o a b s t r a c tArticle history:
Received 25 February 2015
Received in revised form 10 April 2015
Accepted 11 April 2015
Available online 30 April 2015
Keywords:
Brain energy homeostasis
Gray matter pathology
Inﬂammasomes
Astrocyte–neuron lactate shuttle
Multiple Sclerosis
Normal appearing gray matter
Cerebral cortexEmerging as an important correlate of neurological dysfunction in Multiple Sclerosis (MS), extended focal
and diffuse gray matter abnormalities have been found and linked to clinical manifestations such as sei-
zures, fatigue and cognitive dysfunction. To investigate possible underlying mechanisms we analyzed the
molecular alterations in histopathological normal appearing cortical gray matter (NAGM) in MS. By per-
forming a differential gene expression analysis of NAGM of control and MS cases we identiﬁed reduced
transcription of astrocyte speciﬁc genes involved in the astrocyte–neuron lactate shuttle (ANLS) and the
glutamate–glutamine cycle (GGC). Additional quantitative immunohistochemical analysis demonstrating
a CX43 loss in MS NAGM conﬁrmed a crucial involvement of astrocytes and emphasizes their importance
in MS pathogenesis. Concurrently, a Toll-like/IL-1b signaling expression signature was detected in MS
NAGM, indicating that immune-related signaling might be responsible for the downregulation of ANLS
and GGC gene expression in MS NAGM. Indeed, challenging astrocytes with immune stimuli such as
IL-1b and LPS reduced their ANLS and GGC gene expression in vitro. The detected upregulation of IL1B
in MS NAGM suggests inﬂammasome priming. For this reason, astrocyte cultures were treated with
ATP and ATP/LPS as for inﬂammasome activation. This treatment led to a reduction of ANLS and GGC gene
expression in a comparable manner. To investigate potential sources for ANLS and GGC downregulation
in MS NAGM, we ﬁrst performed an adjuvant-driven stimulation of the peripheral immune system in
C57Bl/6 mice in vivo. This led to similar gene expression changes in spinal cord demonstrating that
peripheral immune signals might be one source for astrocytic gene expression changes in the brain.
IL1B upregulation in MS NAGM itself points to a possible endogenous signaling process leading to
ANLS and GGC downregulation. This is supported by our ﬁndings that, among others, MS NAGM astro-
cytes express inﬂammasome components and that astrocytes are capable to release Il-1b in-vitro.
Altogether, our data suggests that immune signaling of immune- and/or central nervous system origin
drives alterations in astrocytic ANLS and GGC gene regulation in the MS NAGM. Such a mechanism might
underlie cortical brain dysfunctions frequently encountered in MS patients.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Multiple Sclerosis (MS) is a chronic inﬂammatory demyelinating
disease of the central nervous system (CNS). MS predominantly
affects young adults and leads to substantial disability in a high pro-
portion of patients (Compston and Coles, 2002). Pathologically, MS
is characterized by multiple demyelinated plaques in the white and
gray matter. Besides that, diffuse white and gray matter
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gaining increasing attention (Graumann et al., 2003; Stadelmann
et al., 2008; Zeis et al., 2008, 2009). In the case of the non-lesional
normal appearing gray matter (NAGM) of MS patients little is
known about the molecular changes which possibly precede gray
matter lesion formation (Dutta et al., 2006, 2007) and potentially
contribute to clinical features encountered in MS. Of those, gray
matter pathology has been linked with physical disability and cog-
nitive impairment (Pirko et al., 2007) as well as fatigue (Roelcke
et al., 1997; Filippi et al., 2002; Niepel et al., 2006), which are com-
mon manifestations of MS (Wishart and Sharpe, 1997; Blinkenberg
et al., 2000; Lazeron et al., 2000; Amato et al., 2004; Benedict et al.,
2004; Morgen et al., 2006; Sanﬁlipo et al., 2006; Houtchens et al.,
2007).
One of the most abundant cell types of the gray matter is the
astrocyte, which fulﬁlls many important tasks ensuring brain func-
tion (Sofroniew and Vinters, 2010). A key assignment of astrocytes
is the removal of neurotransmitters released by neurons via the
glutamate–glutamine cycle (GGC; Schousboe et al., 2014). The dis-
turbance thereof is strongly suggested to be involved in the patho-
genesis of neurological disorders (Seifert et al., 2006). A reduction
of the astroglial excitatory amino acid transporter 2 (EAAT2) was
reported in neuromyelitis optica (NMO; Hinson et al., 2008), an
inﬂammatory demyelinating disease earlier thought to be a variant
of MS (Brosnan and Raine, 2013). Further, in amyotrophic lateral
sclerosis (ALS), a decreased glutamate transport (Rothstein et al.,
1992) as well as a selective loss of EAAT2 was shown (Rothstein
et al., 1995). This suggests that a failure of the GGC by astrocytes
might be crucial for excitotoxic damage and the subsequent patho-
genic process in ALS (Seifert et al., 2006).
Increasing evidence indicate that astrocytes are also important
contributors to CNS metabolism (Sofroniew and Vinters, 2010). In
1994, Pellerin andMagistretti proposed an astrocyte–neuron lactate
shuttle (ANLS) based on existing experimental data (Pellerin and
Magistretti, 1994). This model includes the following sequence of
molecular events: Following increased synaptic activity glutamater-
gic neurons release the neurotransmitter glutamate into the synap-
tic cleft. Glutamate is avidly taken up by the astrocytes surrounding
the synaptic cleft, via speciﬁc glial glutamate transporters (EAAT1
and EAAT2). EAATs co-transport glutamate with sodium ions
increasing intracellular sodium concentration in the astrocyte and
activating the energy dependent Na+/K+ ATPase pump (speciﬁcally
the recruitment of the Na+/K+ ATPase alpha 2 subunit, ATP1A2). The
corresponding hydrolysis of ATP leads to activationof astrocytic gly-
colysis, i.e. the degradation of glucose to pyruvate, which is then
converted to lactate via lactate dehydrogenase (LDH). Lactate is then
released via astrocytic monocarboxylate transporters (MCT1 and 4)
into the extracellular space and from there taken up by the neurons
(via MCT2 transporter), where it serves as an energy substrate fol-
lowing its intracellular conversion to pyruvate (Fig. 1B; Sofroniew
and Vinters, 2010; Pellerin and Magistretti, 2012). This activity
dependent supply of energetic metabolites from astrocytes to neu-
rons is further enabled by a gap-junction mediated astrocyte net-
work allowing intercellular trafﬁcking of metabolites throughout
the astrocyte syncytium (Rouach et al., 2008). Recently, it was
shown that the provision of lactate to neurons is important for
long- as well as short-term memory (Newman et al., 2011; Suzuki
et al., 2011). This suggests that astrocyte dysfunction might play
an important role in the reported cognitive impairments of MS
patients (for review see Ferreira, 2010).
Inﬂammasomes are signaling platforms activated by signs of
tissue damage and metabolic dysfunction (e.g. extracellular ATP),
which lead to the maturation of cytokines such as IL-1b and
thereby drive inﬂammation (Schroder and Tschopp, 2010). They
are composed of an inﬂammasome sensor molecule (usually a
Nod-like Receptor, NLR) and a caspase effector, often coupled viaa signaling adaptor (apoptosis-associated speck-like protein con-
taining CARD, ASC). Inﬂammasomes can be activated by pathogen
associated molecular patterns (PAMPs) and/or danger-associated
molecular patterns (DAMPs; Schroder and Tschopp, 2010).
Activation of inﬂammasomes and secretion of active IL-1b requires
two sequential steps; ‘‘signal 1’’ induces the expression of the inac-
tive cytokine precursor (pro-IL-1b), while ‘‘signal 2’’ triggers its
caspase-1-dependent processing via inﬂammasomes (Schroder
and Tschopp, 2010). In innate immune cells, ‘‘signal 1’’ is usually
provided by pro-inﬂammatory signaling by TLRs, or by IL-1b itself,
whereas ‘‘signal 2’’ might among others be provided by
host-derived molecules indicative of injury e.g. extracellular ATP
(Schroder and Tschopp, 2010). A recent publication by Kawana
et al., 2013 showed that in MS active demyelinating lesions astro-
cytes express all necessary components of the NLRP3 inﬂamma-
some (Kawana et al., 2013). Further, animals lacking Casp1, Nlrp3
or Asc develop a mild clinical course of in experimental autoim-
mune encephalomyelitis (EAE; Furlan et al., 1999; Gris et al.,
2010; Inoue et al., 2012), suggesting an involvement of inﬂamma-
somes in MS pathogenesis.
In our study, we discovered a downregulation of astrocyte
speciﬁc genes involved in the ANLS and the GGC in the MS
NAGM. Additionally, a gene expression signature indicative of acti-
vated Toll-like/Il-1b signaling as well as an upregulation of IL1B
was detected. To investigate a potential interconnection between
Toll-like/Il-1b signaling and the downregulation of astrocyte GGC
and ANLS genes we treated pure astrocyte cultures with IL-1b,
LPS (a TLR4 agonist), ATP (as a potential endogenous dan-
ger/degeneration signal) and with ATP/LPS (inﬂammasome activa-
tion protocol for Il-1b release). These treatments led to a similar
downregulation of genes as found in vivo in the MS NAGM, demon-
strating an interconnection between the Toll-like/IL-1b signaling
and the astrocytic ANLS as well as GGC genes. We further demon-
strated in vivo in C57Bl/6 mice that such an astrocyte reaction in
the MS NAGM can be a consequence of peripheral
immune-system signaling. On the other hand, a downregulation
of GGC and ANLS genes might also be a consequence of an endoge-
nous brain reaction. Supporting this hypothesis, we demonstrated
that IL1B is upregulated in the MS NAGM. Further, astrocytes were
shown to express the necessary inﬂammasome proteins in the MS
NAGM and to be capable of releasing Il-1b in-vitro. Altogether, this
indicates that in MS, immune-or danger related signals induce
ANLS and GGC changes in astrocytes of the NAGM. As astrocyte
dysfunction was shown to play an important role in the reported
cognitive impairments of MS patients (for review see Ferreira,
2010), ANLS or GGC changes might contribute to the encountered
cognitive impairments in MS.
2. Material and methods
2.1. Tissue collection
MS and control brain tissue samples were provided by the UK
Multiple Sclerosis Tissue Bank (UK Multicentre Research Ethics
Committee, MREC/02/2/39), funded by the Multiple Sclerosis
Society of Great Britain and Northern Ireland (registered charity
207495). All brain tissues were routinely screened by a neu-
ropathologist to conﬁrm diagnosis of MS and to exclude other con-
founding pathologies (Reynolds et al., 2011). Tissues used for this
study were immunohistochemically analyzed for MOG (myelin
marker), NeuN (neuronal marker) and CD68 (microglial marker).
Tissues showing demyelination (Supplementary Fig. 1), neuronal
degeneration or strong microglia activation were not included in
the study. In total 31 tissue samples from 17 control as well as
31 tissue samples from 18 MS cases were used for the study
(Table 1).
Table 1
Patient data and tissue used. Clinical and pathological information about the 17 control and 18 MS cases investigated in this study. The number of different tissue blocks used per
case is indicated in parenthesis. (PPMS= primary progressive MS, SPMS= seconday progressive MS, RPMS= relapsing progressive MS)
Patient Gender Age at
death
p.m.
time
Disease
duration
MS
type
Cause of death IHC qRT-PCR Array In-situ
Control patients
C1 m 69 10 Acute cardiac death X (1)
C2 f 59 22 Acute pancreatitis X (1)
C3 m 89 9 Cancer of the rectum X (1) X (1)
C4 f 95 10 Bronchopneumonia X (1)
C5 f 85 9 Cancer of the esophagus X (1) X (1) X (1)
C6 f 93 9 Unknown X (1)
C7 m 73 21 Cardiogenix shock X (1)
C8 m 77 26 Carcinoma of the lung X (1) X (1)
C9 m 64 18 Cardiac failure X (1) X (4) X (1)
C10 f 84 24 Congestive cardiac failure, ischemic heart disease X (1) X (1) X (2)
C11 m 35 22 Carcinoma of the tongue X (4) X (2) X (2) X (1)
C12 f 78 33 Myeloid leukemia X (1)
C13 f 60 13 Ovarian cancer X (1) X (1) X (2)
C14 m 75 17 Aspiration pneumonia X (4) X (1) X (1) X (1)
C15 m 88 22 Prostate cancer, bone metastases X (1) X (1)
C16 f 88 20 Bronchopneumonia X (1) X (1)
C17 m 84 5 Bladder cancer, pneumonia X (2) X (3) X (1) X (1)
Multiple Sclerosis patients
MS1 f 56 8 31 SPMS Breast carcinoma, pneumothorax X (1) X (1) X (1)
MS2 f 58 16 22 PPMS Peritonitis, Multiple Sclerosis X (1) X (1)
MS3 f 78 18 33 SPMS Myocardial infarction, acute abdomen X (1)
MS4 f 58 6 21 PPMS Bronchopneumonia X (3) X (1) X (1) X (1)
MS5 f 20 17 17 PPMS Pulmonary embolus, pneumonia X (2) X (1)
MS6 f 69 11 31 SPMS Acute pyelonephritis, Multiple Sclerosis X (1) X (1)
MS7 f 78 9 47 PPMS Lung infection X (2) X (1) X (1)
MS8 f 78 5 42 SPMS Metastatic carcinoma of bronchus X (4) X (3) X (3) X (1)
MS9 f 54 22 20 SPMS Bronchopneumonia X (2) X (2) X (2)
MS10 m 53 12 11 SPMS Urinary tract infection, Multiple Sclerosis X (1) X (1) X (1)
MS11 m 38 19 17 RPMS Aspiration pneumonia, pulmonary edema X (1) X (1) X (1)
MS12 f 50 12 SPMS Multiple Sclerosis X (1) X (1) X (1)
MS13 m 37 12 27 PPMS Intestinal obstruction, Multiple Sclerosis X (1) X (2) X (1)
MS14 f 78 24 47 SPMS Aspiration pneumonia, Multiple Sclerosis X (2) X (1) X (1) X (1)
MS15 f 49 12 27 PPMS Bronchopneumonia, Multiple Sclerosis X (1) X (2)
MS16 m 45 24 25 SPMS Bronchopneumonia, Multiple Sclerosis X (1) X (1)
MS17 f 47 16 17 SPMS Septicaemia, bronchopneumonia, Multiple
Sclerosis
X (1) X (2) X (1) X (1)
MS18 m 45 9 17 SPMS Multiple sclerosis X (1)
T. Zeis et al. / Brain, Behavior, and Immunity 48 (2015) 313–325 3152.2. RNA proﬁling and statistical analysis
Total RNA was isolated using the RNeasy Kit (Qiagen, Hilden,
Germany) together with Qiazol as lysis reagent. RNA quality control
was done by using the Nanodrop Spectrophotometer (Thermo
Scientiﬁc, Wilmington, USA) and by RNA gel electrophoresis or by
the RNA 6000 Nano total RNA Kit on an Agilent 2100 Bioanalyzer.
Degraded (RIN < 6) and/or contaminated (260/280 nm ratio < 1.5;
230/280 nm ratio < 1.5) samples were excluded from the study.
Gene expression proﬁling using our custom microarrays with
1176 representative cDNA sequences was performed as described
before (Graumann et al., 2003; Zeis et al., 2008). Quantiﬁcation of
differential hybridization signal intensities was done with the
AtlasImage™ 2.0 software program. Normalization of the gene
expression array was performed by using the 10% trimmed mean
as suggested for Human 1.2 Arrays from Clontech (Kroll and
Wolﬂ, 2002). Microarray data analysis was performed with Partek
Genomics Suite software. Differentially expressed genes were iden-
tiﬁed by performing a three-way ANOVA (disease, patients, tissue
type). For this study, genes with a p-value of <0.05 (t-test on dis-
ease) and a mean fold difference of >1.2 were considered to be sig-
niﬁcantly differentially expressed between MS and controls.
Signiﬁcantly differentially expressed genes were further analyzed
with the use of IPA (Ingenuity Systems, www.ingenuity.com). IPA
upstream regulator analysis was performed to detect possible tran-
scriptional regulators (TR) leading to the detected differential geneexpression in MS NAGM. An activation z-score was calculated by
IPA showing whether a potential TR was in an activated
(z-score > 2) or inhibited (z-score < 2) or uncertain state.2.3. Quantitative RT-PCR and statistical analysis
Real-time RT-PCR was performed in 384-well plates (VWR,
Radnor, USA, Cat.No. 82006-678) using the ABI ViiA Fast
Real-Time PCR system (Applied Biosystems, Life technologies
Ltd., Paisley, UK). Primer sequences (Supplementary Table 1) were
designed from unique sites over exon–intron junctions to prevent
ampliﬁcation of genomic DNA. Real-time RT-PCR was performed
according to the manufacturer’s protocol using the KAPA SYBR
Fast Universal 2x qPCR Master mix (KAPA Biosystems, Woburn,
USA). RNA amounts were calculated with relative standard curves
for all mRNAs of interest. Optimal normalization factor for each
experiment was identiﬁed among a set of detectable housekeeping
genes by the NormFinder Software (Andersen et al., 2004). Data of
the qRT-PCR expression analysis are shown as the mean of relative
mRNA levels with error bars representing the standard deviation
(SD). For all experiments, statistical signiﬁcance was determined
using the student’s t-test, *p < 0.05, **p < 0.0001. Unless otherwise
stated, all values were adjusted to the corresponding control group
set to 1.
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Cryostat sections (10 lm) from fresh frozen tissue blocks or cell
culture dishes were ﬁxed for 10 min in 10% formalin. For myelin
staining, sections were delipidated after ﬁxation with methanol
at 20 C for 8 min. Tissue sections and dishes were blocked for
2 h at room temperature (RT) in blocking buffer (PBS pH 7.4, 0.2%
Triton X-100, 0.1% Tween-20, 5% normal donkey serum) and incu-
bated with primary antibodies in blocking buffer overnight at 4 C.
Tissue sections and dishes were then treated with 0.3% hydrogen
peroxide in PBS for 20 min. Sections subjected to immunoﬂuores-
cence were instead incubated for 1 h in 10 mM CuSO4, 50 mM
CH3COONH4, pH 5.0. Next, sections and dishes were incubated
with secondary antibodies in blocking buffer for 1 h at RT.
Sections for peroxidase stainings were processed with the
Vectastain ABC Kit (Vector Laboratories, Burlingame, USA) as
described by the manufacturer. Finally, immunoﬂuorescence sec-
tions and dishes were counterstained with DAPI and mounted
using Fluorosave (Calbiochem, Merck Millipore, Merck KGaA,
Darmstadt, Germany). Antibodies used for immunohistochemical
and immunoﬂuorescence stainings are listed in Table 2.
2.5. Astrocyte cultures
Primary cultures of cerebral cortical astrocytes are prepared
from newborn (1- to 2-days-old) OF1 mice (Charles River
Laboratories, L’Arbresle, France) as previously described (Allaman
et al., 2004; Gavillet et al., 2008). Culture experiments were
approved by the Veterinary Ofﬁce of the State of Vaud. For IL-1b
treatments, culture medium was renewed 24 h before cytokine
treatment induced by addition of IL-1b at 0.25 ng/ml (R&D sys-
tems, Abington, UK) in the culture medium (Gavillet et al., 2008).
Treatment with IL-1b was performed on conﬂuent 21-day-old cul-
tures for 24 h. For ATP/LPS induced inﬂammasome activation,
astrocytes were incubated in serum-free DMEM (D5030) supple-
mented with 5 mM glucose, 44 mM NaHCO3 and 10 mL/L of an
100 antibiotic–antimycotic solution (Invitrogen, Life technologies
Ltd., Paisley, UK) (DMEM) 24 h before treatments. Cells were then
prestimulated with LPS (10 ng/ml) and 4 h later 5 mM ATP was
added for an additional 1 h or 24 h. At the end of the treatment
cells were harvested and total RNA was isolated using the
RNeasy kit (Qiagen, Hilden, Germany). RNA quality control wasTable 2
Antibodies used in this study. Table shows all antibodies, their origin and use in the study.
(C. elegans) 3 (RBFOX3), GFAP = glial ﬁbrillary acidic protein, CD68 = CD68 molecule, OLIG2
a = anti).
Antibody Company
Primary antibodies
anti-MOG (Clone Z12) Kindly provided by Prof. R. Reynolds
anti-NEUN Millipore
anti-GFAP Sigma–Aldrich
anti-CD68 Abcam
anti-OLIG2 Millipore
anti-MCT1 Kindly provided by Dr. Merenzhinskaya, Washington DC, U
anti-GJA1 (Cx43) Abcam
anti-EAAT2 Abcam
anti b-Actin (AC-74) Sigma–Aldrich
Secondary antibodies
dk-a-m-Biotin Jackson ImmunoResearch
gt-a-rb-Biotin Jackson ImmunoResearch
dk-a-rb-Cy2 Jackson ImmunoResearch
dk-a-rb-Cy3 Jackson ImmunoResearch
dk-a-m-Cy2 Jackson ImmunoResearch
dk-a-m-Cy3 Jackson ImmunoResearch
gt-a-m-Alexa680 Molecular Probes
gt-a-rb-IRDye 800 Rockland Immunochemicals, Inc.done by using the Nanodrop Spectrophotometer (Thermo
Scientiﬁc, Wilmington, USA) and by the RNA 6000 Nano total
RNA Kit on an Agilent 2100 Bioanalyzer. Degraded (RIN < 6) and/or
contaminated (260/280 nm ratio < 1.5; 230/280 nm ratio < 1.5)
samples were excluded from the study. For protein analysis cells
were lysed in 62.5 mM Tris–HCl pH 6.8, 50 mM DTT and 0.3%
SDS, sonicated for 10 s, boiled for 5 min at 100 C and stored at
80 C.
Using this culture procedure, >99% of the cells were immunore-
active for the astrocytic marker glial ﬁbrillary acidic protein
(GFAP), and microglia (CD68) were almost complete absent
(<0.01%). No signiﬁcant cell death upon any treatment was
detected by the calcein survival test (data not shown).
2.6. Western blot analysis
Protein samples fromthe astrocyte cultureswere subjected togel
electrophoresis using a 4–12%NUPAGE gradient gel (Invitrogen, Life
technologies Ltd., Paisley, UK). After blotting on 0.2 lm Immun-Blot
PVDF membranes (BIO-RAD, Hercules, USA), blots were incubated
with blocking buffer (3% TOP-BLOCK in TBS) for 1 h at RT.
Membranes were incubated with primary antibodies in blocking
buffer overnight at 4 C. After several washing steps membranes
were incubated with secondary ﬂuorescence-labeled antibody for
1 h at RT, washed four times with TBST and scanned using the
Odyssey Western System (LICOR Systems, Lincoln, USA).
Antibodies used for Western blot analysis are listed in Table 2.
2.7. CX43 analysis
CX43 analysis was performed on cerebral cortex using 19 gray
matter tissue blocks from 12 control cases and 24 NAGM tissue
blocks from 15 MS cases (Table 1). Average staining intensity
was measured for 20 segments throughout the cortical layers (an
example is given in Fig. 3A and C). For every tissue block all possi-
ble gyri were measured and an average staining intensity for all 20
segments for every tissue block was calculated. Intensity values of
each block were normalized to the staining intensity of the
non-lesioned adjacent normal appearing white matter (NAWM;
showing no signiﬁcant differences between control and MS
patients) to correct for possible minor staining artefacts. Values
from different blocks from the same patients were then combined(MOG = myelin oligodendrocyte protein, NeuN = RNA binding protein, fox-1 homolog
= oligodendrocyte transcription factor 2, dk = donkey, gt = goat, rb = rabbit, m = mouse,
Cat.Nr. Used for IHC Dilution Used for WB Dilution
– X 1:200
MAB377 X 1:500
G-3893 X 1:2000
ab845 X 1:500
ab9610 X 1:500
SA – X 1:500 X 1:1000
ab11370 X 1:500 X 1:10000
ab49645 X 1:500
A2228 X 1:5000
715-065-150 X 1:500
111-065-144 X 1:500
711-225-152 X 1:500
711-165-152 X 1:500
715-225-150 X 1:500
715-165-150 X 1:500
A21048 X 1:10000
611-132-002 X 1:10000
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20 segments was then calculated by performing a two-way
ANOVA (Disease, Segments). To further assess a possible reduction
of CX43 in control gray matter tissue, a hypothetic ‘‘evenly stained’’
group was created by calculating the average intensity for all 20
segments by using data from all tissue blocks without a reduction
in CX43 immunoreactivity. Differences between this virtual group
and control and MS cases were then evaluated by using the
Holm-Sidak method, with alpha = 5.000%.
2.8. In situ hybridization
Synthetic digoxigenin-labeled riboprobes (cRNA) were gener-
ated from recombinant pCRTMII-Topo plasmid containing a
723 bp cDNA insert of human MCT1 sequence (50-11-733-30) and a
836 bp cDNA insert of human IPAF sequence (50-50-865-30).
Transcription was done from both sides with either SP6 or T7 RNA
polymerase, generating antisense or sense (control) cRNA probes.
Further, synthetic digoxigenin-labeled riboprobes (cRNA)were gen-
erated fromrecombinantpBSKSII plasmid containinga823 bp cDNA
insert of human CASP4 sequence (50-56-878-30), a 130 bp cDNA
insert of human ASC sequence (50-600-729-30), a 539 bp cDNA insert
of human NALP1 sequence (50-2541-3079-30), and a 713 bp cDNA
insert of human NALP3 sequence (50-2693-3405-30). Transcription
was done fromboth sideswith either T3 or T7 RNApolymerase, gen-
erating antisense or sense (control) cRNA probes. In situ hybridiza-
tion was performed on 14 lm cryosections of freshly frozen
tissues as described previously (Schaeren-Wiemers and
Gerﬁn-Moser, 1993; Graumann et al., 2003). In situ hybridization
signal was revealed by alkaline phosphatase with BCIP and NBP as
substrate. Immunohistochemistry was performed as described
above. Antibodies used for immunohistochemical stainings are
listed in Table 2.2.9. ELISA
For determination of Il-1b secretion, astrocytes were stimulated
with LPS, ATP or ATP/LPS for either 1 or 24 h (see above for treat-
ments conditions). Il-1b concentration was measured by ELISA
using the ELISA MAX Deluxe Set Mouse Il-1b Kit (Biolegend, San
Diego, USA) according to the manufacturer’s instructions.2.10. CFA-induced peripheral immune stimulation in C57/Bl6 mice
8 weeks old C57Bl/6 mice were bred in-house and kept together
in groups of ﬁve. Four independent experiments were made with 5
(pilot study) or 10 mice per treatment group. Mice were anaes-
thetized with 3% isoﬂurane and immunized subcutaneously in
the ﬂanks with either 0.1 ml PBS with 0.1 ml complete Freund’s
adjuvant (CFA) containing 0.4 mg Mycobacterium tuberculosis
(CFA/PT) or with 0.2 ml PBS (Control). 200 ng pertussis toxin was
injected intraperitonally on the day of immunization and two days
later. Injections were made in the SPF animal facility. Animals were
euthanatized using carbon dioxide and subsequent decapitation.
Spinal cord tissue was dissected at day 14 after immunization.
All experiments were approved by the Veterinary Ofﬁce of the
State of Basel. Sample size was estimated by using the following
assumptions derived from earlier experiments (Difference of
means = 20%; common standard deviation = 30%; alpha = 0.05;
power = 80%). Both, male and female animals were randomly
assigned to the treatment groups, and the analysis was performed
by a nonblinded investigator. In total, 35 control and 34 CFA/PT
injected mice were analyzed. One animal of the CFA/PT group
was excluded due to bad RNA quality. No adverse events were
noted during all experiments.3. Results
3.1. Metabolic genes are downregulated in chronic MS NAGM
To identify molecular alterations in cortical MS NAGM, a differ-
ential gene expression analysis was performed. 8 control and 13
MS cases (Table 1) were investigated using a custom microarray
containing 1176 representative cDNA sequences. In MS NAGM,
we found a signiﬁcantly decreased expression of genes involved
in the ANLS and in the GGC; for example the monocarboxylate
transporter 1 (MCT1; Solute carrier family 16, member 1,
SLC16A1) and the excitatory amino acid transporter 2 (EAAT2;
GLT-1; solute carrier family 1, member 2, SLC1A2; Fig. 1A and B).
Additionally, a downregulation of connexin 43 (CX43, gap junction
protein, alpha 1, GJA1) was detected (Fig. 1A and B).
In order to validate and substantiate our observations we ana-
lyzed additional NAGM tissues of up to 14 control and 17 MS cases
by qRT-PCR. We further enlarged our analysis by additional genes
functionally connected to the ones identiﬁed by the microarray,
e.g. genes from the ANLS to which MCT1 belongs to, as well as
additional genes of the GGC (Fig. 1A and B). Results from the
qRT-PCR conﬁrmed the transcriptional downregulation of MCT1,
CX43, EAAT2, glutamine synthetase (GLUL) and glucose transporter
type 1 (GLUT1; solute carrier family 2 (facilitated glucose trans-
porter, member 1, SLC2A1). Additionally, we detected a signiﬁcant
downregulation of N-system amino acid transporter 1 (NAT1;
solute carrier family 38, member 3, SLC38A3) and ATPase,
Na+/K+ transporting, alpha 2 polypeptide (ATP1A2). In contrast,
an upregulation of lactate dehydrogenase A (LDHA) was found.
All genes of interest (Fig. 1A) were further evaluated whether their
expression pattern is inﬂuenced by confounding factors such as
post-mortem delay time, age at death, disease duration, clinical
course or gender. Neither signiﬁcant correlation nor differential
expression due to any of these confounding factors could be
identiﬁed.3.2. MCT1, CX43 and EAAT2 are expressed in astrocytes in MS NAGM
MCT1, CX43 as well as EAAT2 are expressed by astrocytes in
human brain (Milton et al., 1997; Rouach et al., 2002; Pellerin
et al., 2005; Pierre and Pellerin, 2005; Chiry et al., 2006). To
conﬁrm their expression pattern in MS NAGM we performed
immunohistochemistry and immunoﬂuorescence co-localization
studies. MCT1 staining was strongest on blood vessels and, addi-
tionally, a diffuse staining of the neuropil was evident (Fig. 2A,
inset shows a blood vessel and the surrounding neuropil at higher
magniﬁcation). Immunoﬂuorescence co-localization microscopy of
MCT1 and GFAP demonstrates MCT1 expression in human cortical
astrocytes (Fig. 2B, arrows). The expression pattern of CX43 in MS
NAGM was variable within the cortical layers (Fig. 2C, inset shows
a single CX43-positive astrocyte at higher magniﬁcation).
Immunoﬂuorescence co-localization microscopy of CX43 and
GFAP conﬁrmed the exclusive cellular expression of CX43 in
human astrocytes (Fig. 2D, arrow). Finally, the glutamate trans-
porter EAAT2 was also detected to be expressed exclusively in
astrocytes of the MS NAGM (Fig. 2E and F).
Currently, a controversial discussion is taking place in the scien-
tiﬁc community concerning the localization of MCT1 expression in
brain tissue. As IHC stainings of MCT1 showed an overall diffuse
staining of the neuropil, we have performed an additional in situ
hybridization analysis to further validate the cellular expression
pattern of MCT1 within the human cerebral cortex. We found a
widespread MCT1 expression in many different cell types such as
in endothelial cells of blood vessels (Fig. 2G and H, arrowhead),
in astrocytes identiﬁed by immunohistochemistry for GFAP
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Fig. 1. Differential gene expression in normal appearing cortical gray matter of chronic MS. (A) Table shows microarray and qRT-PCR expression data of selected genes, which
are differentially expressed in MS NAGM. Genes belonging to the ANLS and the GGC were in general downregulated in MS NAGM. Data are presented as mean fold change and
unadjusted p-value. P-values were calculated by performing a three-way ANOVA (Microarray: n = 11 control, n = 16 MS cases; qRT-PCR: n = 20 control, n = 22 MS cases). (B)
Schematic drawing of genes belonging to the ANLS and GGC. This model includes the following sequence of molecular events: Following increased synaptic activity
glutamatergic neurons release the neurotransmitter glutamate into the synaptic cleft. Glutamate is avidly taken up by the astrocytes surrounding the synaptic cleft, via
speciﬁc glial glutamate transporters (EAAT1 and EAAT2). EAATs co-transport glutamate with sodium ions increasing intracellular sodium concentration in the astrocyte and
activating the energy dependent Na+/K+ ATPase pump (through the recruitment of the alpha 2 subunit). The corresponding hydrolysis of ATP leads to activation of astrocytic
glycolysis, i.e. the degradation of glucose to pyruvate, which is then converted to lactate via lactate dehydrogenase (LDH). Lactate is then released via astrocytic
monocarboxylate transporters (MCT1 and 4) into the extracellular space and from there taken up by the neurons (via MCT2). In neurons it serves as an energy substrate
following its intracellular conversion to pyruvate by LDH. Genes which were found by qRT-PCR to be highly signiﬁcantly (p 6 0.001) downregulated in MS NAGM are shown
in dark green (in bold), genes with a higher p-value showing a tendency to be downregulated are shown in light green. Genes showing a tendency to be upregulated are
shown in light red. Red bolt indicates coupling of glutamate transport with glucose utilization. Abbreviations: Gluc = glucose, Pyr = pyruvate, La = lactate, Glu = glutamate,
Gln = glutamine. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
318 T. Zeis et al. / Brain, Behavior, and Immunity 48 (2015) 313–325(Fig. 2H, arrows), in a subpopulation of cortical neurons identiﬁed
by NeuN (Fig. 2I, arrow) and in Olig2-positive cells (Fig. 2J, arrows).
Altogether, our data conﬁrm the expression of MCT1, CX43 and
EAAT2 in astrocytes in the MS NAGM.
3.3. CX43 protein reduction in MS NAGM is characterized by its loss in
individual astrocytes
Reduced expression of CX43 as well as the inhomogeneous CX43
protein expression pattern in MS NAGM (Fig. 2C) prompted us to
investigate the expression pattern of CX43 in control andMS cortex
inmore detail.Whereas theNAGMofmost of theMS caseswas char-
acterized by a selective absence of CX43 in individual astrocytes
(Fig. 3A and B), such a CX43 loss was found to a much lesser extent
in the gray matter of control cases (Fig. 3C and D).
The reduction of CX43was not homogenous throughout the cor-
tical layers. Instead the reduction was observed in individual astro-
cyteswithin layers III–Vwith single astrocytes still expressing CX43
(e.g. Figs. 3A, B and 2C inset). In some cases the reduction of CX43
was so profound that only few Cx43 positive astrocytes remained
as a thin rim in layer I and layer VI (Fig. 3B as an example). To quan-
tify the CX43 reduction in MS NAGM, we measured CX43 staining
intensity over all layers of the gray matter from 12 control and 14
MS cases (Fig. 3E and F). For each case, we measured the average
CX43 staining intensity of 20 segments reaching from layer I to layer
VI (Fig. 3A and C) and normalized it to the adjacent white matter
staining intensity to account forminor staining artifacts (no statisti-
cal signiﬁcant difference was detected between control and MS
white matter CX43 staining). Statistical analysis over the segments
from MS NAGM versus controls revealed that the CX43 expression
was signiﬁcantly more reduced in MS NAGM than in control gray
matter ( p < 0.0001, Two-way ANOVA) with an average reduction
of about 32% throughout all layers (Fig. 3E). If compared to a virtual
‘‘evenly stained’’ group, generated from tissues with an even CX43
staining throughout all layers (e.g. Fig. 3C), MS NAGM but also con-
trol gray matter were statistically signiﬁcantly different (p < 0.0001for both, Holm-Sidak’s multiple comparisons test; Fig. 3F). As in a
study of human autopsy tissue additional factors may affect CX43
immunoreactivity, we investigated whether the degree of CX43
reduction correlateswith post-mortemdelay time, age at death, dis-
ease duration or gender. No signiﬁcant correlation or differencewas
found due to these possible confounding factors (data not shown). A
comparable immunohistochemical staining pattern as for CX43was
also detected for EAAT2 (Fig. 2E). This suggests that EAAT2 expres-
sion might be reduced in individual astrocyte as observed for
CX43. Taken together, our analysis demonstrates that CX43, the
major gap junction protein expressed by astrocytes and involved
in the formation of the astrocyte syncytium, is downregulated in
MS NAGM most prominently in layers III–V. A recent study identi-
ﬁed a higher CX43 expression in MS cortical NAGM in comparison
to control samples (Markoullis et al., 2014). Whether this discrep-
ancy is due to the smaller sample number investigated or to the
heterogeneous expression of CX43, which we also observed in con-
trol cases, cannot be veriﬁed.3.4. Differential gene expression in MS NAGM is indicative of immune-
related signaling
Simultaneously to the downregulation of metabolic genes in MS
NAGM, the inﬂammasome associated cytokine, interleukin-1beta
(IL1b), was signiﬁcantly upregulated in MS (Fig. 4A). In keeping
with this, Ingenuity pathway upstream analysis (Ingenuity
Systems, www.ingenuity.com) of the microarray data identiﬁed a
Toll-like/IL-1b signaling expression signature to be present in the
differential gene expression pattern of MS NAGM (IL1 group activa-
tion z-score 4.748, IL1B activation z-score 3.538; LPS/TLR4 activa-
tion z-score 4.441; Fig. 4A). Further, additional immune-related
signaling signatures were found in the differential gene expression
pattern of MS NAGM (e.g. TNF, IL2, IFNG; Fig. 4A). Together, this
strongly suggests that gene expression in MS NAGM is inﬂuenced
by immune-related signaling.
Fig. 2. Expression pattern of MCT1, CX43 and EAAT2 in NAGM of MS cerebral cortex. (A and B) MS NAGM showing immunoreactivity for MCT1. (A) Immunoreactivity to
MCT1 was strongest on blood vessels and a diffuse staining of the neuropil was evident. (B) Immunoﬂuorescence colocalization shows astrocytes (arrows) co-expressing
MCT1 (green) and GFAP (red). (C and D) Immunoreactivity for CX43 in the MS NAGM. (C) Single astrocytes positive for CX43 are visible in the MS NAGM with reduced CX43.
(D) Astrocyte (arrow) expressing CX43 (green) and GFAP (red). (E and F) Immunoreactivity to EAAT2 in MS NAGM. (E) Single astrocytes are expressing EAAT2 in the MS
NAGM. (F) Double-labeling of EAAT2 (green) and GFAP (red) showing astrocytes (arrows) expressing EAAT2 in the MS NAGM. (G–J) In situ hybridization for MCT1 in control
cortex counterstained with DAPI (G), and in MS NAGM counterstained with GFAP (H), with NeuN (I) and with Olig2 (J). Scale bars: A, C, E = 500 lm, insets = 20 lm, B, D,
F = 20 lm, G–J = 50 lm. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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immune-related signaling
The upregulation of IL1B aswell as the immune-related signaling
signatures and the downregulation of ANLS and GGC genes in MS
NAGM lead to the question whether these phenomenons are inter-
connected. Therefore,we investigatedwhether immune-related sig-
naling directly affect astrocyte ANLS and GGC gene expression. For
that, we chose IL-1b, which was upregulated in MS NAGM and
whose signaling signature was detected in the MS NAGM, and the
mediator of the identiﬁed second most signiﬁcant signaling signa-
ture, the TLR4 agonist LPS (Fig. 4A). We treated mouse primary cor-
tical astrocyte cultures with either 0.25 ng/ml IL-1b or 10 ng/ml LPS
for 24 h. qRT-PCR analysis of treated astrocytes revealed signiﬁcant
transcriptional downregulation of Cx43,Glul, Ldhb,Glut1,Nat1 (IL-1b
and LPS treatment), and Eaat1 and Atp1a2 (LPS treatment only),
whereas the expression of Eaat2 and the astrocyte speciﬁcmonocar-
boxylate transporter Mct4 (Solute carrier family 16, member 3,
Slc16a3) (both upon LPS treatment) were signiﬁcantly upregulated
(Fig. 4B). Western blot analysis as well as immunoﬂuorescence
stainings conﬁrmed strong downregulation of Cx43 on the proteinlevel (Fig. 4C and F). In the case of Mct1, a signiﬁcant upregulation
couldbedetected (Fig. 4B)whereas its protein expressionwas rather
the opposite (Fig. 4C). The unchanged or slightly upregulated
expression of EAAT2 and the induction of MCT1 mRNA expression
in pure astrocyte cultures might be due to the lack of their normal
cellular counterparts such as neurons and oligodendrocytes in the
cerebral cortex. Our ﬁndings show that cultured astrocytes exposed
to immune-related stimuli such as IL-1b andLPS alter the expression
of their ANLS and GGC genes substantially.
3.6. ANLS and GGC genes are differentially expressed upon
inﬂammasome activation
The upregulation of IL1B in MS NAGM suggests priming or even
activation of inﬂammasomes in the tissue. To investigate whether
inﬂammasome activation can also take place in astrocytes and
whether this inﬂuences gene expression of the ANLS and GGC com-
ponents, we treated cortical astrocyte cultures with ATP alone,
mimicking possible tissue damage in MS, as well as with ATP plus
LPS in a similar manner as described for inﬂammasome activation
(Schroder and Tschopp, 2010; Zhou et al., 2011). In general,
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Fig. 3. CX43 protein loss in NAGM of MS cerebral cortex. (A–D) Representative images of CX43 stained cortical brain areas from MS (A and B) and control (C and D) cases
showing different CX43 staining patterns. (E) Quantiﬁcation of the average CX43 intensity in MS relative to control cases (set to 1) over all cortical segments (1–20) is shown.
MS tissues show a reduction in CX43 staining intensity over all segments ranging from 19% in segment 1 to 43% in segment 9 with an average overall reduction of 32%. (F)
Average relative CX43 intensity in MS and control tissue samples in comparison to intensity values from evenly stained cortices over all cortical segments is shown (all
segments normalized to the overall average intensity of evenly stained cortices set as 1). MS but also control patients show a reduction in CX43 staining intensity over all
segments. Scale bar(A–D) = 1 mm.
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Cx43, Ldhb, Glut1, Nat1, Eaat1 and Mct4 as well as Atp1a2 if treated
by ATP/LPS (Fig. 4D). In contrast, Glul expression was signiﬁcantly
upregulated by both treatments (Fig. 4D) as well as Atp1a2 if trea-
ted with ATP alone. Whereas Eaat2 andMct1where downregulated
by ATP treatment, ATP/LPS treatment led to an upregulation of
these genes. For Mct1, this is in line with the data obtained from
the LPS and IL-1b treatment (Fig. 4B). Western blot analysis as well
as immunoﬂuorescence stainings conﬁrmed the strong downregu-
lation of Cx43 on the protein level (Fig. 4E and F), and also Mct1
protein expression was slightly but signiﬁcantly downregulated
(Fig. 4E). Taken together, our data demonstrate that astrocytes
challenged with inﬂammasomal triggers respond by changing the
expression of genes involved in the ANLS and GGC.
3.7. Peripheral inﬂammation signals reduce Mct1 and Cx43 expression
in the spinal cord of C57/Bl6 mice
In MS, immune-related signaling might origin from immuno-
logical processes (e.g. lesion formation) in regions far away of the
investigated MS NAGM tissue. Therefore, we asked the question
whether signaling from the activated immune system can lead to
a response in the gray matter tissue similar to that observed in
MS NAGM brain tissue and in astrocyte cultures. To test this
hypothesis we treated C57Bl/6 mice with a subcutaneous injection
of 100 ll CFA with 100 ll PBS in the base of the tail, and twice per-
tussis toxin i.p. according to the standard EAE protocol. Injection of
myelin auto-antigen was omitted to exclude possible T cell inﬁltra-
tion and to limit the immunological reaction to the outside of the
CNS. In order to detect CNS gene expression changes also due to
possible signaling by primed T cell whose accumulation in the
meninges peaks around d11-12 after EAE induction (Kivisakk
et al., 2009), spinal cord tissues were dissected at day 14 after
CFA injection. Gene expression in cervical spinal cord was then
analyzed by qRT-PCR. This protocol, which does not lead to the
development of demyelinating lesions in the CNS, caused a small
but persistent signiﬁcant downregulation of Mct1 and Cx43(Fig. 5A). No changes in gene expression were seen at that stage
for Eaat1 and 2, Glul, Ldha, Ldhb, Atp1a2, Nat1 as well as Glut1 (data
not shown). Whether the expression of these genes has already
normalized after the CFA injection or whether they will be changed
later or not at all has to be further elucidated. However, our data
show that a CNS-unspeciﬁc inﬂammation in the periphery can lead
to alterations of CNS metabolic gene expression.
3.8. Inﬂammasome components are expressed in human cerebral
cortex
The upregulated IL1B expression, together with the found IL-1b
signaling signature in the MS NAGM raised the question whether
inﬂammasome activation might participate in MS NAGM alter-
ations. Therefore,weﬁrst investigated if speciﬁcNLR inﬂammasome
sensor molecules (NLRC4, NLRP1, NLRP3), the inﬂammasome adap-
tor ASC, and caspase effectors (CASP1, CASP4) are expressed in con-
trol andMSNAGM. In situ hybridization analysis demonstrated that
these inﬂammasome components are expressed throughout the
human cortex (Fig. 5B). We could demonstrate that CASP4, ASC,
NLRC4, NLRP1, and NLRP3 were expressed in astrocytes (Fig. 5B,
arrows). This indicates that astrocytes in vivo are capable to elicit
inﬂammasome activation.
3.9. Cortical astrocytes are capable to release IL-1b upon
inﬂammasome activation
The upregulation of IL1B in MS NAGM further provides evidence
that immune-related signaling leading to a disturbance in astro-
cyte metabolic processes may take place in the tissue itself. As
IL1Bwas upregulated and astrocytes expressed the necessary com-
ponents for inﬂammasome activation we investigated whether
these cells could be induced to trigger inﬂammasome-dependent
IL-1b release. The expression proﬁling of NAGM indicated that
IL1B gene expression was induced in MS patients as compared
healthy controls (Fig. 4A), suggesting that ‘‘signal 1’’of the activa-
tion cascade has already occurred in MS NAGM. We thus
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Fig. 4. Differential expression pattern of ANLS andGGC genes of culturedmouse astrocytes treatedwith IL-1b, LPS, ATP andATP/LPS. (A) IL1B is upregulated in corticalMSNAGM
tissue in comparison to control graymatter. Further, IPA upstream regulator analysis suggested possible upstream signaling by immune related regulators such as e.g. IL1B, LPS,
TNF, IL2 and IFNG. (B) qRT-PCR analysis of mouse primary astrocyte cultures treatedwith IL-1b or LPS for 24 h. Mean values ± SD of relativemRNA levels (normalized to control
cultures set to 1) for differentially expressed ANLS and GGC genes are shown (n = 18 for control, n = 6 for IL-1b and n = 8 for LPS, 3 independent experiments). (B) Quantitative
Western blot analysis showingmean values ± SD of relative protein levels (normalized to control cultures set to 1) are shown forMct1 and Cx43 (n = 12 for each, 3 independent
experiment). (D) qRT-PCRanalysis ofmouseprimary astrocyte cultures treatedwithATPorATP andLPS (ATP/LPS) for 24 h.Meanvalues ± SDof relativemRNA levels (normalized
to control cultures set to 1) for selected ANLS genes are shown (n = 18 for controls, n = 8 for ATP and n = 11 for ATP/LPS treated cultures, 3 independent experiments). (E)
QuantitativeWestern blot analysis of mouse primary astrocyte cultures treated with ATP and LPS (ATP/LPS) for 24 h. Mean values ± SD of relative protein levels (normalized to
control cultures set to 1) are shown for Mct1 and Cx43 (n = 12 for both conditions, 3 independent experiments). (F) Immunoﬂuorescence staining for Cx43 (green) of mouse
control astrocyte cultures and astrocyte cultures treatedwith IL-1b, LPS, ATP and ATP/LPS shows the reduction of Cx43 in the treated cultures. All cultures looked as shown in the
bottom left control picture stained for Cx43, GFAP (as a marker for astrocytes) and DAPI. For all experiments, statistical signiﬁcance was determined using the student’s t-test,
*p < 0.05, **p < 0.0001. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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gene in primary astrocytes, as is already established for immune
cells. Indeed, LPS strongly upregulated Il1b gene expression, com-
pared to control astrocyte cultures where Il1b gene expression
was below the detection limit (data not shown).
We then treated cortical astrocyte cultures with LPS alone (sig-
nal 1 alone), ATP alone (signal 2 alone), or LPS plus ATP (both sig-
nals 1 and 2) as described for Nlrp3 inﬂammasome activation
(Schroder and Tschopp, 2010; Zhou et al., 2011) and measured
IL-1b release. While LPS strongly induced the expression of the
Il1b gene in primary astrocytes (data not shown), IL-1b release
was weak and present only after 24 h treatment (Fig. 5C).
Treatment with ATP alone did neither induce Il1b expression nor
IL-1b release. However, strong IL-1b release, although only minor
Il1b induction, required cell stimulation with both LPS and ATP
(Fig. 5C), which is in line with studies in immune cells.4. Discussion
Beside lesions, which are considered to be the pathological hall-
mark ofMS, numerousmolecular alterations have been identiﬁed in
the so-called normal-appearing tissue (Graumann et al., 2003;
Lindberg et al., 2004; Dutta et al., 2006, 2007; Zeis et al., 2008,
2009). Among these processes, alterations of the gray matter are of
particular interest since they appear to be associated with clinical
deﬁcits and disease course of MS. Magnetic resonance imaging
(MRI) studies for example revealed a strong correlation between
gray matter atrophy and future disability progression (Amato
et al., 2007; Fisher et al., 2008). Gray matter pathology has further
been linked with physical disability and cognitive impairment
(Pirko et al., 2007) as well as fatigue (Roelcke et al., 1997; Filippi
et al., 2002; Niepel et al., 2006), which are common manifestations
of MS (Wishart and Sharpe, 1997; Blinkenberg et al., 2000;
Lazeron et al., 2000; Amato et al., 2004; Benedict et al., 2004;
Morgen et al., 2006; Sanﬁlipo et al., 2006; Houtchens et al., 2007).
However, to date the precise pathological alterations underlying
these manifestations is not known. To investigate molecular mech-
anisms possibly underlying these impairments in MS we analyzed
the molecular alterations in histopathological normal appearing
gray matter in MS.
Transcriptional proﬁling revealed that MS NAGM is associated
with the downregulation of gene transcripts involved in the GGC
and in the ANLS (Fig. 1B), an experimentally-based framework pro-
posed byMagistretti and coworkers (Pellerin andMagistretti, 1994;
Bittar et al., 1996; Pellerin et al., 1998;Magistretti et al., 1999). In the
ANLS concept, neuronal activity is coupled to astrocytic glucose uti-
lization involving an activation of aerobic glycolysis in astrocytes
and lactate consumption by neurons (Pellerin et al., 2007).
Reduction of the ANLS might lead to a decrease in
activity-dependent lactate delivery to neurons, and thus to a
decrease in neuronal activity as suggested in the study of Dutta
and coworkers (Dutta et al., 2006). Such a mechanism was hypoth-
esized as a possible cause for central or mental fatigue (Ronnback
and Hansson, 2004), which is observed in the majority of MS cases.
Astrocyte–neuron lactate transport is also required for memory for-
mation (Newman et al., 2011; Suzuki et al., 2011). Hence, chronic
reduction of this particular energy supply, as suggested by our ﬁnd-
ings, might lead to some of the observed cognitive impairments in
MS (for review see Ferreira, 2010). Further, they might also have
an impact on synaptic activity in the cerebral cortex especially in
layer III–V, the major in- and output of the cerebral cortex. Exactly
in these regions we detected the strongest reduction of CX43 and
potentially of the glutamate transporter EAAT2. A similar reduction
of the astroglial EAAT2 was also found in neuromyelitis optica
(NMO; Hinson et al., 2008), an inﬂammatory demyelinating diseaseearlier thought to be a variant of MS (Brosnan and Raine, 2013).
Changed expression of CX43 as well as EAAT2 was suggested to be
crucially involved in memory processes (Frisch et al., 2003;
Stehberg et al., 2012; Poletti et al., 2014). In summary, a reduced
ANLS and GGC gene expression in theMSNAGMmight lead tomany
of the encountered clinical features of MS such as fatigue, cognitive
impairment or physical disability as discussed before.
The biological activity of IL-1b is controlled by signaling com-
plexes called inﬂammasomes (Schroder and Tschopp, 2010), which
are emerging as central drivers of innate immune function
(Martinon et al., 2009). Concomitant to ANLS and GGC gene down-
regulation, the expression of the gene encoding the
pro-inﬂammatory cytokine IL-1b was upregulated. Further, and
in keeping with IL1B gene induction, in silico upstream regulator
analysis revealed gene signatures indicative of Il-1b signaling, sug-
gesting innate immune activation in MS NAGM. This is supported
by reports showing elevated expression of the purinergic receptor
P2X ATP-gated ion channel 7 (P2X7R), mediating ATP-dependent
NLRP3 activation, in the spinal cord of MS patients (Yiangou
et al., 2006). Also, elevated levels of the NLRP3 agonist uric acid
were found in the CSF of MS patients (Amorini et al., 2009). As
the receptor for IL-1b is ubiquitously expressed among all brain
cell types (Allan et al., 2005), a chronic exposure of gray matter tis-
sue to IL-1b in MS patients as suggested by our differential gene
expression analysis may be a crucial factor driving MS pathogene-
sis. In rats, intracerebral administration of IL-1b led to oligodendro-
cytes apoptosis (Fan et al., 2009), and subarachnoid injection of
proinﬂammatory cytokines such as TNF and IFNc lead to subpial
demyelination (Gardner et al., 2013). Chronic IL-1b release, as
suggested by the global upregulation of IL1B in MS NAGM, may
be further pathologically relevant as it was reported to lead to neu-
ronal death mediated by astrocytes (Thornton et al., 2006).
The concomitant presence of immune-related signaling signa-
tures, potential inﬂammasomal activation as well as downregula-
tion of ANLS and GGC genes in MS NAGM suggests that these
phenomenons are interconnected. Treatment experiments of cul-
tured cortical astrocytes demonstrated that this is indeed the case
in-vitro. We found that in all treatments made (IL-1b, ATP, LPS and
ATP/LPS), genes from the ANLS as well as the GGC have been down-
regulated in vitro. This demonstrates a direct link between
immune-related signaling and the expression of ANLS and GGC
genes in astrocytes, resembling our observations for MS NAGM
in vivo. These ﬁndings are in line with reports showing that
pro-inﬂammatory cytokines can modulate the astrocytic metabolic
phenotype (Gavillet et al., 2008). This suggests that in MS,
immune-related signaling, either from brain exogenous or endoge-
nous sources lead to a reduction in ANLS andGGC genes. Finally, this
might result in cognitive impairments as discussed before. A possi-
ble impact of immune-related signals on cognition is further sup-
ported by the ﬁndings of long-term cognitive impairment among
survivors of severe sepsis (Iwashyna et al., 2010). Additionally,
peripheral inﬂammationwas reported to acutely impair humanspa-
tial memory (Harrison et al., 2014).
Although gene expression regulation of treated astrocytes
resembles gene regulation in MS NAGM, some genes showed a dif-
ferent expression behavior. This is mostly true for MCT1 and
EAAT2. The use of pure astrocyte cultures to investigate immune
mediated changes in their gene expression offers methodological
advances. However, they are likely to exhibit different properties
than those in vivo (Halim et al., 2010). We suspect that in a con-
trolled culture environment with constant glutamate supply,
downregulation of EAAT2 might be overruled. In the case of
MCT1, Nijland et al., 2014 showed that MCT1 is strongly upregu-
lated in MS white matter lesions whereas its expression is reduced
in perilesional areas (Nijland et al., 2014). We therefore speculate
that MCT1 expression in astrocytes is dependent on their reactivity
NLRP1
NLRC4
NLRP3
CASP4 ASC
B.
C.
IL
1
se
cr
et
io
n 
(p
g/
m
l)
0
50
100
150
200
250
24h
1h
** **
Control LPS ATP ATP/LPS
**
re
la
tiv
e 
m
R
N
A 
ex
pr
es
si
on
Mct1 Cx43
0.6
0.7
0.8
0.9
1.0
1.1
1.2
Control
CFA/PT
**
**
A.
Fig. 5. Exogenous and endogenous signaling as a source for ANLS and GGC downregulation. (A) qRT-PCR analysis of spinal cord tissues of C57/Bl6 mice immunized with CFA
and pertussis toxin showing the mean value ± SD of relative mRNA levels (normalized to control mice set to 1) for Mct1 and Cx43 (n = 35 for controls, n = 34 for CFA/PT, 4
independent experiments). (B) In situ hybridization of cortical gray matter tissue sections was performed for CASP4, ASC, NLRC4 (IPAF), NLRP1 (NALP1) and NLRP3 (NALP3).
The hybridization signal was revealed by alkaline phosphatase with NBT/BCIP leading to a blue precipitate and an immunohistochemical staining for GFAP was made for
collocation with astrocytes. In situ hybridization signals revealed that components of the inﬂammasome complex are expressed, among others, in astrocytes of the human
cortex. Bars = 50 lm. (C) ELISA of primary astrocyte cultures showing the mean values ± SD for IL-1b secreted into the medium of cultures treated for 1 h or 24 h without
(control) or with LPS, ATP or ATP/LPS (n = 9 at 1 h, n = 18 at 24 h, 3 independent experiments). For all experiments, statistical signiﬁcance was determined using the student’s
t-test, * p < 0.05, ** p < 0.0001. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
T. Zeis et al. / Brain, Behavior, and Immunity 48 (2015) 313–325 323state. Our treatment might, in the case of MCT1, activate astrocytes
to a higher degree so that MCT1 gets upregulated as e.g. in MS
white matter lesions. In contrast, astrocytes of the NAGM might
be activated to a lesser extent, downregulating MCT1 as shown
in MS perilesional areas (Nijland et al., 2014).
Immune-related signaling in MS NAGM can be of brain exoge-
nous but also endogenous origin. Downregulation of Cx43 and
Mct1 in the in vivo adjuvant driven peripheral immunization
experiment provides evidence that ANLS gene expression alter-
ations in the MS NAGM might result from peripheral events and
subsequent immune-related signaling to the brain tissue. Recent
investigations detected TNF and IFNc in inﬂamed meninges and
in cerebrospinal ﬂuid of MS cases (Gardner et al., 2013), which
could act as such proinﬂammatory stimuli. Further, Dujmovic
et al., 2009 demonstrated elevated IL-1b levels in the CSF and sera
of MS patients (Dujmovic et al., 2009). As it was shown that cytoki-
nes can be transported through the blood brain barrier (for review
see Banks et al., 1995), continuous and/or repetitive inﬂammatory
events, such as lesion formation, might lead to the observed down-
regulation of ANLS and GGC genes in MS NAGM. However,
immune-related signaling in MS NAGM might also be of endoge-
nous origin. This notion is supported by the ﬁnding of a CX43 loss
in the middle of the NAGM in layer III-V. Immune-related signaling
from exogenous sources as e.g. from the meninges as recently
suggested (Magliozzi et al., 2010; Gardner et al., 2013) would most
probably lead to a gradient of CX43 loss from layer I towards layer
VI as e.g. shown for neuronal loss (Magliozzi et al., 2010). Loss of
CX43 due to immune-related signaling from blood vessels would
further be expected to strike the whole NAGM rather than a
demarcated zone in layer III–V. An endogenous signaling is alsosupported by the upregulated expression of IL1B in the MS
NAGM itself, lacking immune cell inﬁltration as a source for this
gene expression. Finally, besides microglia known to express
inﬂammasomes and release cytokines and chemokines
(Benveniste, 1997), an intrinsic signaling by activated astrocytes
might be the source of MS NAGM ANLS and GGC downregulation
as we could show that astrocytes themselves express the necessary
inﬂammasome components and can be stimulated to release IL-1b.5. Conclusion
Although recent progress has been made in MS treatment to
date (Kappos et al., 2010), clinical disability continues to rise in
MS patients over time. Our study demonstrates that in MS patients,
astrocytes display a differential ANLS and GGC gene expression
phenotype that is a likely cause for encountered clinical features
in MS such as fatigue, cognitive impairment or physical disability.
Further, we posit that the observed astrocyte differential gene
expression in MS can be caused by immune-related signaling
(e.g. inﬂammasomes) of exogenous but also endogenous origin.
Our ﬁndings highlight the importance of subtle gray matter
changes in MS pathogenesis, and the need to develop therapies
to interfere with the responsible molecular pathways (e.g. IL-1b)
to ameliorate clinical symptoms of MS.Conﬂict of interest
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